कृपया अन्य खोज का प्रयास करें
OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX201A for idiopathic pulmonary fibrosis; OLX301 for age-related macular degeneration; and OLX301D for subretinal fibrosis. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Jayakrishna Ambati | - | - | Member of Scientific Advisory Board |
Samir Mitragotri | - | - | Member of Scientific Advisory Board |
Jong-Nam Seo | 59 | - | Director |
Aaron Hakim | - | 2020 | Member of Scientific Advisory Board |
Yury V. Popov | - | 2020 | Member of Scientific Advisory Board |
Demetrios G. Vavvas | - | 2019 | Member of Science & Technology Advisory Board |
Dong-Ki Lee | 49 | - | CEO & Director |
Sung-Hwa Hong | 64 | - | Director |
Hye-Won Chung | - | 2019 | Member of Scientific Advisory Board |
Gordon Jiang | - | 2020 | Member of Scientific Advisory Board |
John Lis | - | - | Member of Scientific Advisory Board |
Sun-Woo Hong | 48 | - | Director |
Tae-Gyeong Kim | 54 | - | Independent Outside Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है